Cross-sectional analysis shows health-related quality of life correlates with clinical data in ankylosing spondylitis, indicating biologic therapy's impact.
Key Points
61.3% of patients reported poor quality of life, highlighting significant lifestyle impacts.
Positive correlations between ASQoL and multiple factors including BASDAI, BASFI, and work impairment suggest therapy's relevance.
Using specific indices like BASDAI and BASFI helped assess disease severity and its impact on quality of life.
Routine HRQoL assessments may enhance clinical management strategies for ankylosing spondylitis patients.